Emphysema symptoms are not always immediately apparent. In fact, some people can have the condition for several years before they experience any noticeable discomfort. Typically, the first sign to appear is shortness of breath, which is usually mild at first and gradually intensifies over time. Most people seek treatment when their breathing difficulties cause them to avoid certain activities and interfere with their quality of life.
In addition to shortness of breath and a general feeling that they can’t get enough air, many people with emphysema experience additional symptoms such as:
- Persistent coughing
- Excessive mucus production
- Chest pain or tightness
- General fatigue
- Loss of appetite
Traditionally, several approaches have been used to help relieve the symptoms of emphysema. Some patients benefit from the use of bronchodilators, inhaled steroids, antibiotics, pulmonary rehabilitation, nutrition therapy and/or supplemental oxygen. However, while these techniques can help with symptom control, they cannot address the underlying cause of emphysema within the lungs. To achieve this, lung volume reduction surgery or a lung transplant may be recommended, but usually only in very severe cases.
For patients who are looking for an alternative treatment for emphysema and its symptoms, the Lung Institute offers a promising option. Specifically, we use autologous cells derived from a patient’s own body to help promote healing within the lungs and potentially slow the progression of lung damage. The latter aspect is especially important because emphysema has no cure — it is a chronic condition that worsens over time.
If traditional forms of treatment for emphysema symptoms have not provided you with the relief you need, you may benefit from the Lung Institute’s groundbreaking alternative. To learn more about cellular therapy for chronic lung conditions, contact us at 888-745-6697. Our innovative treatments are performed on an outpatient basis, and comprehensive follow-up care is provided by our caring medical team.